Sergio Maimone
Research Subjects
Sergio Maimone has a total of 269 co-authors. Here are the top co-authors by number of shared publications:
Giovanni Raimondo
Division of Clinical and Molecular Hepatology, University Hospital of Messina, Messina, Italy; Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
10 shared publicationsGiovanni Squadrito
Department of Clinical and Experimental Medicine University of Messina Messina Italy
9 shared publications- Vincenza Calvaruso
University of Palermo
9 shared publications Angela Alibrandi
Department of Economics Unit of Statistical and Mathematical Science of Messina University of Messina Messina Italy
8 shared publications- Giovanni Raimondo
Department of Clinical and Experimental Medicine University of Messina Messina Italy
8 shared publications - Irene Cacciola
Department of Clinical and Experimental Medicine University of Messina Messina Italy
8 shared publications
Latest Publications
- 16 May 2026
- Published by Springer Nature in Acta Diabetologica
- Vol. 63 (7) , 1-2
GLP-1 RA semaglutide for alcohol use disorder: a potential multi-target therapy
- 16 May 2026
- Published by Springer Nature in Acta Diabetologica
- Vol. 63 (7) , 1-2
GLP-1 RA semaglutide for alcohol use disorder: a potential multi-target therapy
- Top Cited PapersOpen Access
- 21 May 2024
- Published by Elsevier in Journal of Hepatology
- Vol. 81 (4) , 641-650
Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis
- 21 May 2024
- Published by Elsevier in Journal of Hepatology
- Vol. 81 (4) , 641-650
Top Cited PapersOpen AccessMyosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis
- 8 July 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 77 (6) , 1731-1732
Response to: A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial]
- 8 July 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 77 (6) , 1731-1732
Response to: A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial]
- 26 May 2021
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 67 (6) , 2655-2665
Cirrhotic Patients with Bacterial Infection and Negative Cultures Have a More Advanced Disease and an Increased Short-Term Mortality Rate
Background The negative clinical impact of bacterial infections (BI) in patients with cirrhosis is well documented. In cirrhotic patients, failure to isolate the pathogen is a frequent event, occurring in 30–40% of cases. Aim The aim of this study was to compare the clinical characteristics, early (30-day) and short-term (90-day) mortality rates, in a cohort of cirrhotic patients with BI, between those with positive (C-pos) and those with negative (C-neg) microbiological cultures. Methods We retrospectively enrolled 279 consecutive hospitalized cirrhotic patients with BI. Survival and predictors of 30-day and 90-day mortality were assessed by Kaplan–Meier curves and logistic regression analysis, respectively. Results Cultures tested negative in 108/279 (38.7%) patients. C-neg patients were more frequently males (p = 0.035), had higher Child–Pugh–Turcotte (CPT; p = 0.007) and model for end-stage liver disease-sodium (MELD-Na; p = 0.043) scores, and had more frequently decompensated liver disease (p = 0.04). Mortality rate was higher in C-neg than in C-pos patients, both at 30 days (22.2% versus 11.7%, p = 0.024) and 90 days (46.3% versus 33.3%, p = 0.030). MELD-Na score and non-selective beta-blockers (NSBBs) were independent risk factors for 30-day and 90-day mortality. In particular, the use of NSBBs was independently associated with a lower 30-day and 90-day mortality risk (OR 0.41, CI95% 0.17–0.94, p = 0.040; and OR 0.43, CI95% 0.25–0.75, p = 0.003, respectively). Conclusions Cirrhotic patients with BI and negative microbiological cultures have significantly higher mortality compared to those with positive cultures. Early mortality and short-term mortality are mainly influenced by the underlying severity of liver disease. In this contest, therapy with NSBBs has a positive impact on short-term survival.
- 26 May 2021
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 67 (6) , 2655-2665
Cirrhotic Patients with Bacterial Infection and Negative Cultures Have a More Advanced Disease and an Increased Short-Term Mortality Rate
Background The negative clinical impact of bacterial infections (BI) in patients with cirrhosis is well documented. In cirrhotic patients, failure to isolate the pathogen is a frequent event, occurring in 30–40% of cases. Aim The aim of this study was to compare the clinical characteristics, early (30-day) and short-term (90-day) mortality rates, in a cohort of cirrhotic patients with BI, between those with positive (C-pos) and those with negative (C-neg) microbiological cultures. Methods We retrospectively enrolled 279 consecutive hospitalized cirrhotic patients with BI. Survival and predictors of 30-day and 90-day mortality were assessed by Kaplan–Meier curves and logistic regression analysis, respectively. Results Cultures tested negative in 108/279 (38.7%) patients. C-neg patients were more frequently males (p = 0.035), had higher Child–Pugh–Turcotte (CPT; p = 0.007) and model for end-stage liver disease-sodium (MELD-Na; p = 0.043) scores, and had more frequently decompensated liver disease (p = 0.04). Mortality rate was higher in C-neg than in C-pos patients, both at 30 days (22.2% versus 11.7%, p = 0.024) and 90 days (46.3% versus 33.3%, p = 0.030). MELD-Na score and non-selective beta-blockers (NSBBs) were independent risk factors for 30-day and 90-day mortality. In particular, the use of NSBBs was independently associated with a lower 30-day and 90-day mortality risk (OR 0.41, CI95% 0.17–0.94, p = 0.040; and OR 0.43, CI95% 0.25–0.75, p = 0.003, respectively). Conclusions Cirrhotic patients with BI and negative microbiological cultures have significantly higher mortality compared to those with positive cultures. Early mortality and short-term mortality are mainly influenced by the underlying severity of liver disease. In this contest, therapy with NSBBs has a positive impact on short-term survival.
- Open Access
- 24 April 2021
- Published by Wiley in Liver International
- Vol. 41 (9) , 2059-2067
Over time evaluation of glycaemic control in direct‐acting antiviral‐treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis
Background: Data concerning the impact of hepatitis C virus (HCV) cure on type 2 diabetes mellitus (T2DM) are controversial. The aim of the study was to evaluate the effects of anti‐HCV direct‐acting antiviral (DAA) treatments on long‐term glucose control in HCV/T2DM patients with chronic hepatitis C (CHC) or with cirrhosis.Methods: One hundred and eighty‐two consecutive HCV/T2DM patients who achieved a viral clearance by DAA treatment were enrolled. Seventy or 182 of them had CHC, and 112 had cirrhosis. Clinical, biochemical and instrumental parameters were recorded at baseline and at 48, 96 and 120 weeks (48w, 96w and 120w, respectively) after stopping DAA therapy.Results: At baseline, the overall study population had a mean of glycated haemoglobin (HbA1c) value of 7.2% (ranging from 5 to 11.2), without any significant differences between CHC and cirrhosis [7.1 and 7.2, respectively]. Evaluation over time of HbA1c variations showed a significant improvement of glucose control at all post‐treatment time points compared with baseline in CHC patients (P = .001). In cirrhotic patients, a significant decrease of HbA1c levels was only found when comparing HbA1c values between baseline and 48w time‐point (P = .001), whereas this improvement disappeared at both 98w and 120w (P = .8 and P = .3, respectively). Multivariate logistic regression analysis showed that patients with chronic hepatitis have a 2.5 (CI 1.066‐5.945) times greater chance of achieving an improvement of glycaemic values than patients with liver cirrhosis (P = .035).Conclusion: DAA‐based HCV cure induces a significant and persistent amelioration of glycaemic control in HCV/diabetic patients with chronic hepatitis, whereas cirrhotic HCV/diabetic subjects have only a transient benefit from the virus elimination.
- 24 April 2021
- Published by Wiley in Liver International
- Vol. 41 (9) , 2059-2067
Open AccessOver time evaluation of glycaemic control in direct‐acting antiviral‐treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis
Background: Data concerning the impact of hepatitis C virus (HCV) cure on type 2 diabetes mellitus (T2DM) are controversial. The aim of the study was to evaluate the effects of anti‐HCV direct‐acting antiviral (DAA) treatments on long‐term glucose control in HCV/T2DM patients with chronic hepatitis C (CHC) or with cirrhosis.Methods: One hundred and eighty‐two consecutive HCV/T2DM patients who achieved a viral clearance by DAA treatment were enrolled. Seventy or 182 of them had CHC, and 112 had cirrhosis. Clinical, biochemical and instrumental parameters were recorded at baseline and at 48, 96 and 120 weeks (48w, 96w and 120w, respectively) after stopping DAA therapy.Results: At baseline, the overall study population had a mean of glycated haemoglobin (HbA1c) value of 7.2% (ranging from 5 to 11.2), without any significant differences between CHC and cirrhosis [7.1 and 7.2, respectively]. Evaluation over time of HbA1c variations showed a significant improvement of glucose control at all post‐treatment time points compared with baseline in CHC patients (P = .001). In cirrhotic patients, a significant decrease of HbA1c levels was only found when comparing HbA1c values between baseline and 48w time‐point (P = .001), whereas this improvement disappeared at both 98w and 120w (P = .8 and P = .3, respectively). Multivariate logistic regression analysis showed that patients with chronic hepatitis have a 2.5 (CI 1.066‐5.945) times greater chance of achieving an improvement of glycaemic values than patients with liver cirrhosis (P = .035).Conclusion: DAA‐based HCV cure induces a significant and persistent amelioration of glycaemic control in HCV/diabetic patients with chronic hepatitis, whereas cirrhotic HCV/diabetic subjects have only a transient benefit from the virus elimination.
- 1 October 2019
- Published by Elsevier in Digestive and Liver Disease
- Vol. 51 (10) , 1490-1492
Sodium load and intravenous antimicrobials in patients with cirrhosis
- 1 October 2019
- Published by Elsevier in Digestive and Liver Disease
- Vol. 51 (10) , 1490-1492
Sodium load and intravenous antimicrobials in patients with cirrhosis
- 1 June 2019
- Published by Elsevier in Digestive and Liver Disease
- Vol. 51 (6) , 843-849
Erectile dysfunction in compensated liver cirrhosis
- 1 June 2019
- Published by Elsevier in Digestive and Liver Disease
- Vol. 51 (6) , 843-849
Erectile dysfunction in compensated liver cirrhosis
- 1 March 2019
- Published by Elsevier in Digestive and Liver Disease
- Vol. 51 (3) , 438-442
The present profile of chronic hepatitis B virus infection highlights future challenges
- 1 March 2019
- Published by Elsevier in Digestive and Liver Disease
- Vol. 51 (3) , 438-442
The present profile of chronic hepatitis B virus infection highlights future challenges
- 17 December 2018
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 64 (5) , 1335-1345
Predictors of Re-bleeding and Mortality Among Patients with Refractory Variceal Bleeding Undergoing Salvage Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Transjugular intrahepatic portosystemic shunt (TIPS) has proven clinical efficacy as rescue therapy for cirrhotic patients with acute portal hypertensive bleeding who fail endoscopic treatment.
- 17 December 2018
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 64 (5) , 1335-1345
Predictors of Re-bleeding and Mortality Among Patients with Refractory Variceal Bleeding Undergoing Salvage Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Transjugular intrahepatic portosystemic shunt (TIPS) has proven clinical efficacy as rescue therapy for cirrhotic patients with acute portal hypertensive bleeding who fail endoscopic treatment.